Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease

Cancer

Volumn 101, Issue 3, 2004, Pages 558-566

  Srkalovic, Gordan ^a   Cameron, Marte G ^b   Rybicki, Lisa ^a   Deitcher, Steven R ^a   Kattke Marchant, Kandice ^a   Hussein, Mohamad A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Avdeling Sandnessjøen ^*  (Norway)

Author keywords

Monoclonal gammopathy of undetermined significance; Multiple myeloma; Plasma cell dyscrasia; Venothrombosis

Indexed keywords

ALBUMIN; IMMUNOGLOBULIN G; PARAPROTEIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANAMNESIS; ARTICLE; CANCER PATIENT; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GAMMOPATHY; HUMAN; HYPERCOAGULABILITY; IMMOBILIZATION; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL DYSCRASIA; POPULATION; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PARAPROTEINEMIAS; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL ANALYSIS; THALIDOMIDE; THROMBOEMBOLISM;

EID: 3242778603     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20405     Document Type: Article

References (32)

1. Anderson FA Jr., Wheeler HB. Venous thromboembolis. Risk factors and prophylaxis. Clin Chest Med. 1995;16:235-251.
2. Anderson FA Jr., Wheeler HB. Physician practices in the management of venous thromboembolism: a community-wide survey. J Vasc Surg. 1992;15:707-714.
3. Heattiarachchi RJ, Lok J, Prins MH, et al. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators and diagnosis. Cancer. 1998;83:180-185.
4. Ahmed Z, Mohyuddin Z. Deep vein thrombosis as a predictor of cancer. Angiology. 1996;47:261-265.
5. Prandoni P, Lensing AWA, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128-1133.
6. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
7. Bowcock SJ, Rassam SM, Ward SM, et al. Thromboembolism in patients on thalidomide for myeloma. Hematology. 2002;7:51-53.
8. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001;344:1951-1952.
9. Cavo M, Zamagni E, Cellini C, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood. 2002;100:2272-2273.
10. Urbauer E, Kaufmann H, Nosslinger T, et al. Thromboembolic events during treatment with thalidomide. Blood. 2002;99:4247-4248.
11. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
12. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implication for therapy. Blood. 2002;100:1168-1171.
13. Anonymous. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
14. Jacobson JL, Hussein MA, Barlogie B, et al. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003;122:441-450.
15. Editorial. Inside Haematologica: caution in the use of thalidomide for treatment of hematological disorders. Haematologica. 2002;87:34-35.
16. Ershler WB, Keller ET. Age-associated increased interleukine-6 gene expression, late-life diseases and frailty. Annu Rev Med. 2000;51:245-270.
17. Kaufmann H, Urbauer E, Ackermann J, et al. Advances in the biology and therapeutic management of multiple myeloma. Ann Hematol. 2001;80:445-451.
18. Suwa T, Hogg JC, English D, et al. Interleukin-6 induces margination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol. 2000;279:H2954-H2960.
19. Wong GG, Witek-Giannotti JS, Temple PA, et al. Stimulation of murine hemopoetic colony formation by human IL-6. J Immunol. 1988;140:3040-3044.
20. Seymour JF, Talpaz M, Hagemeister FB, et al. Clinical correlates of elevated serum levels of interleukine 6 in patients with untreated Hodgkin's disease. Am J Med. 1997;102:21-28.
21. Kyle RA, Therneau TM, Rajkumar SV, et al. A long term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
22. Kerr R. Interleukin 6 and hemostasis. Br J Haematol. 2001;115:3-12.
23. Srkalovic G, Elson P, Trebisky B, et al. Use of melphalan, thalidomide and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med Oncol. 2002;19:219-226.
24. Zangari M, Barlogie B, Thertulien R, et al. The increased risk of DVT observed in thalidomide treated multiple myeloma patients is associated with newly diagnosed status and combination chemotherapy, but not adversely effect survival [abstract]. Proc Am Soc Clin Oncol. 2003;22:584.
25. Gabriel DA, Smith LA, Folds JD, et al. The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J Lab Clin Med. 1983;1:545-552.
26. Lackner H, Hunt V, Zuker MB, et al. Abnormal fibrin ultra-structure, polymerization and clot retraction in multiple myeloma. Br J Haematol. 1970;18:625-636.
27. Coleman M, Virgliano EM, Weksler ME, et al. Inhibition of fibrin monomer polymerization by lambda myeloma globulins. Blood. 1972;39:210-223.
28. Carr ME, Dent RM, Carr SL. Abnormal fibrin structure and inhibition of fibrinolysis in patients with mutliple myeloma. J Lab Clin Med. 1996;128:83-88.
29. Haim N, Lanir N, Hoffman R, et al. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med. 2001;110:91-96.
30. Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002;13:187-192.
31. Deitcher SR, Choueiri T, Srkalovic G, Hussein MA. Acquired activated protein C resistance (APC-R) in myeloma patients with venous thromboembolic events (VTE). Br J Haematol. 2003;123(5):959.
32. Bertina RM, Koeleman BP, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.